In the BioHarmony Drug Report Database
Glycerol phenylbutyrate
Ravicti (glycerol phenylbutyrate) is a small molecule pharmaceutical. Glycerol phenylbutyrate was first approved as Ravicti on 2013-02-01. It has been approved in Europe to treat inborn urea cycle disorders. Ravicti’s patent is valid until 2032-03-09 (FDA).
Trade Name
|
Ravicti |
|---|---|
Common Name
|
glycerol phenylbutyrate |
ChEMBL ID
|
CHEMBL2105745 |
Indication
|
inborn urea cycle disorders |
Drug Class
|
Image (chem structure or protein)